Integra LifeSciences Quarterly Cash Flow Statement
NASDAQ: IARTHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 13.50 +0.45%
Integra LifeSciences free cash flow
In the quarter ended Jun 30, 2026, Integra LifeSciences generated $22.8 million of operating cash flow and spent $12.3 million on capital expenditures. That left free cash flow of $10.5 million, a free-cash-flow margin of 2.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Integra LifeSciences cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 4.48M | -4.62M | -1.70M | -5.40M | -484.07M | -25.29M | 19.43M | -10.70M | -12.40M | -3.28M | 19.83M | 19.50M |
| Net Income growth (YoY) | — | — | -108.77% | — | — | — | -2.01% | -154.85% | -396.41% | -113.54% | -62.54% | -60.94% |
| Stock-Based Compensation | 5.84M | 5.17M | 5.84M | 5.58M | 5.29M | 1.87M | 7.15M | 4.38M | 7.24M | 5.60M | 5.79M | 5.46M |
| Change in Working Capital | -19.52M | -9.12M | 3.92M | 6.32M | -15.52M | -8.49M | -36.77M | 13.66M | 22.95M | -22.56M | -14.74M | -22.99M |
| Operating Cash Flow | 22.80M | 9.80M | 11.82M | 40.91M | 8.92M | -11.26M | 50.74M | 22.48M | 40.40M | 15.76M | 58.75M | 26.77M |
| Capital Expenditures | -12.31M | -14.85M | -17.21M | -15.16M | -20.15M | -28.92M | -29.60M | -29.65M | -29.71M | -15.46M | -24.54M | -13.08M |
| Investing Cash Flow | -43.28M | -14.85M | -34.91M | -15.59M | -21.65M | -35.92M | -4.25M | -10.40M | -322.20M | -53.97M | -57.23M | -7.70M |
| Share Repurchases | — | — | 0 | 0 | — | — | -2.47M | 0 | -50.00M | 0 | 0 | -125.00M |
| Financing Cash Flow | -818.00K | 8.30M | 24.34M | -10.24M | -21.14M | 35.38M | -7.15M | -19.91M | -93.75M | 358.68M | -6.89M | -49.66M |
| Net Change in Cash | -22.39M | 1.76M | 2.86M | 14.27M | -21.19M | -7.27M | 31.22M | -79.00K | -376.67M | 315.50M | 2.67M | -35.46M |
| Free Cash Flow | 10.49M | -5.04M | -5.40M | 25.75M | -11.23M | -40.18M | 21.14M | -7.16M | 10.69M | 291.00K | 34.22M | 13.69M |
This table shows 12 quarterly periods of Integra LifeSciences's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow IART's reporting calendar. What is a cash flow statement?